301. 黄斑ジストロフィー Macular dystrophy Clinical trials / Disease details


臨床試験数 : 46 薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05244304
(ClinicalTrials.gov)
March 28, 202220/1/2022Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent SubjectsStargardt Disease 1Drug: Tinlarebant;Drug: PlaceboBelite Bio, IncNULLRecruiting12 Years18 YearsAll60Phase 3China;France;Germany;Hong Kong;Netherlands;Switzerland;Taiwan;United Kingdom;Australia;Belgium;United States
2NCT05266014
(ClinicalTrials.gov)
March 12, 202126/1/2022This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt DiseasePhase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt DiseaseStargardt DiseaseDrug: tinlarebantRBP4 Pty LtdBelite Bio, IncActive, not recruiting12 Years18 YearsAll13Phase 1/Phase 2Australia;Taiwan